Predicting Relapse in Pancreatic Neuroendocrine Tumors

Researchers have found a new way to classify non-functional pancreatic neuroendocrine tumors (PNETs) in order to predict which patients will experience relapse. Most PNETs are non-functional, meaning that they do not release excess hormones into the bloodstream. In current practice, patients whose non-functional PNETs are larger than 2 cm are considered at the highest risk of metastatic recurrence following surgery. "As clinical behaviors [of non-functional PNETs] vary widely and distant metasta...
Continue reading

Metastatic Merkel Cell Carcinoma: Treatment Challenges and Best Practices With Paul Nghiem, MD, PhD

Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine tumor of unknown origin that typically presents in older white and immunocompromised adults. An estimated 1,500 cases are diagnosed in the United States annually. The rapid rise of MCC incidence during the past few decades has been attributed in part to people living longer with increased sun exposure and weakened immune systems, a feature that suggests an infectious origin and warrants further research. Treatment standards are ...
Continue reading

Iobenguane I 131 Approved for Treatment of Adrenal Gland Tumors

The FDA has granted approval to iobenguane I 131 (Azedra, Progenics Pharmaceuticals, Inc.) for the treatment of iobenguane scan-positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (PPGL)—rare neuroendocrine tumors with a poor prognosis and limited treatment options—in adult and pediatric patients who require systemic anticancer therapy. Approval was based on an open-label, single-arm, multicenter clinical trial which evaluated 68 patients (aged ≥12 years) wit...
Continue reading

Lutetium Lu 177 Dotatate Approved for GEP-NETS

The FDA approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc.) for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults. Approval was based on data from NETTER-1, a randomized, multicenter, open-label, active-controlled trial in 229 patients with progressive, well-differentiated, locally advanced/inoperable or metastatic som...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.